Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2401 - 2425 of 15107 in total
Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. In June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.[L47092,L47127] It was further...
Approved
Investigational
Matched Description: … 12 years and older. ... This makes ritlecitinib a highly selective and irreversible JAK3 inhibitor. ... [L48181] Ritlecitinib is administered orally and is the first member of its class. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Oteseconazole is an azole metalloenzyme inhibitor that targets fungal CYP51. CYP51, also known as 14α demethylase, participates in the formation of ergosterol, a compound that plays a vital role in the integrity of cell membranes.[L41635,A247020] By binding and inhibiting CYP51, oteseconazole is active against most microorganisms associated with recurrent vulvovaginal...
Approved
Investigational
Matched Description: … [L41635,A247020] By binding and inhibiting CYP51, oteseconazole is active against most microorganisms ... Candida glabrata_, _Candida krusei_, _Candida parapsilosis_, _Candida tropicalis_, _Candida lusitaniae_ and ... L41635] Unlike previous-generation azole antifungals, oteseconazole has a high selectivity for CYP51 and
Matched Categories: … Triazole and tetrazole derivatives …
Belumosudil is used in the treatment of chronic graft-versus-host disease (GVHD) and has been investigated for the treatment of pulmonary arterial hypertension. It is an inhibitor of rho-associated coiled-coil-containing protein kinases (ROCK), with significantly more selectivity for ROCK2 as compared to ROCK1 (IC50 100 nM vs. 3 μM, respectively). In...
Approved
Investigational
Matched Description: … Belumosudil is used in the treatment of chronic graft-versus-host disease (GVHD) and has been investigated ... HSCT), belumosudil helps to resolve immune dysregulation by shifting the balance between Th17 cells and ... July 2021, under the brand name Rezurock, for the treatment of chronic GVHD in patients who have tried and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Attapulgite is a magnesium aluminium phyllosilicate which occurs in a type of clay soil common to the Southeastern United States. When used in medicine, it physically binds to acids and toxic substances in the stomach and digestive tract. For that reason, it has often been used in antidiarrheal medications. Until...
Approved
Vet approved
Matched Description: … When used in medicine, it physically binds to acids and toxic substances in the stomach and digestive …
Matched Categories: … Alimentary Tract and Metabolism …
Lebrikizumab is a monoclonal antibody against IL-13 that binds to a different epitope compared tralokinumab.[A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 years and older with a body weight...
Approved
Investigational
Matched Description: … adolescent patients 12 years and older with a body weight of at least 40 kg. ... EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and ... This approval is based on the positive results obtained from the Phase 3 studies ADvocate 1 and ADvocate …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Lorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity. It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety. Lorcaserin is...
Approved
Withdrawn
Matched Description: … It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought ... Safety Communication requesting the manufacturer of Belviq (lorcaserin hydrochloride tablets, 10 mg) and ... hydrochloride extended-release tablets, 20 mg) to voluntarily withdraw these products from the U.S. market, and
Matched Categories: … Alimentary Tract and Metabolism …
Pyrvinium is an anthelmintic effective for pinworms. Several forms of pyrvinium have been prepared with variable counter anions, such as halides, tosylate, triflate and pamoate. Pyrvinum's anti-cancer properties are currently under investigation.
Approved
Matched Description: … forms of pyrvinium have been prepared with variable counter anions, such as halides, tosylate, triflate and
Matched Categories: … Antiparasitic Products, Insecticides and Repellents …
Naftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans and Epidermophyton floccosum.
Approved
Matched Description: … , Trichophyton mentagrophytes, Trichophyton tonsurans and Epidermophyton floccosum. ... Naftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical ... treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum …
Iloperidone is a benzisoxazole and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009. It is considered to be a second-generation antipsychotic drug with multiple receptor binding profile, although it shows high affinity towards 5-HT2A and dopamine D2 receptors. Iloperidone is currently used to...
Approved
Matched Description: … Iloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved ... ] with multiple receptor binding profile, although it shows high affinity towards 5-HT2A and ... [A263547] Iloperidone is currently used to treat schizophrenia and manic or mixed episodes associated …
Gadopiclenol is a gadolinium-based contrast agent (GBCA) based on a pyclen macrocyclic structure. It is indicated for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system and the body. In 2006, the use of GBCAs was associated with the development...
Approved
Matched Description: … hardening of skin and subcutaneous tissues. ... vascularity in the central nervous system and the body. ... It is indicated for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal …
Ponesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults.[A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than fingolimod. Fingolimod's activity at sphingosine 1-phosphate receptor 3 was suspected to...
Approved
Investigational
Matched Description: … sphingosine 1-phosphate receptor 3 was suspected to be responsible for a portion of it's adverse effects, and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha sterol demethylase...
Approved
Matched Description: … These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. …
Matched Categories: … Triazole and tetrazole derivatives ... Metabolic Side Effects of Drugs and Substances …
An indandione that has been used as an anticoagulant. Phenindione has actions similar to warfarin, but it is now rarely employed because of its higher incidence of severe adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)
Approved
Investigational
Matched Categories: … Blood and Blood Forming Organs …
A disaccharide of glucose and galactose in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.
Approved
Experimental
Investigational
Matched Description: … A disaccharide of glucose and galactose in human and cow milk. ... It is used in pharmacy for tablets, in medicine as a nutrient, and in industry. …
Matched Categories: … Diet, Food, and Nutrition …
Asthma is a heterogeneous chronic obstructive respiratory disease with both "type 2" (T2) and T2-low endotypes characterized by reduced airflow, chronic inflammation, and airway remodelling.[A243764, A243769] Thymic stromal lymphopoietin (TSLP), an innate pleiotropic IL-2-family cytokine, has emerged as a key upstream regulator of chronic inflammation across asthma endotypes. Blocking the...
Approved
Investigational
Matched Description: … including eosinophil counts and IgE, FeNO, IL-5, and IL-13 levels. ... endotypes characterized by reduced airflow, chronic inflammation, and airway remodelling. ... Asthma is a heterogeneous chronic obstructive respiratory disease with both "type 2" (T2) and T2-low …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases.[A221451,A221456] The disease is associated with extra-articular manifestations, progressive disability, and comorbidities including cardiovascular disease and mental disorders. 50-70% of patients with RA are unable to...
Approved
Investigational
Matched Description: … [A189165] JAK2 and JAK3 play important roles in both immune and hematologic functions; therefore, selectivity ... joint symptoms and can limit range of motion in severe cases. ... comorbidities including cardiovascular disease and mental disorders. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Carbamoylcholine, also known as carbachol, is a muscarinic agonist discovered in 1932. Carbamoylcholine was initially used as a treatment for migraines, induction of diuresis, and other parasympathetic effects. Carbamoylcholine was granted FDA approval on 28 September 1972.
Approved
Matched Description: … Carbamoylcholine was initially used as a treatment for migraines,[A226365] induction of diuresis,[A226370] and
Matched Categories: … Antiglaucoma Preparations and Miotics …
Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment...
Approved
Investigational
Matched Description: … Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high ... MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and ... patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.
Approved
Investigational
Vet approved
Matched Description: … It is active against gram-negative bacteria and used for the treatment of gonorrhea. …
Yeast allergenic extract is used in allergenic testing.
Approved
Matched Categories: … Alimentary Tract and Metabolism …
Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed...
Approved
Investigational
Matched Description: … human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and ... soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL ... [A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations. However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and guanosine diphosphate...
Approved
Investigational
Matched Description: … KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations ... of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and ... Adagrasib targets KRASG12C, one of the most common KRAS mutations, at the cysteine 12 residue and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Ebola virus (EBOV) remains an important human pathogen within the Ebolavirus genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid...
Approved
Matched Description: … neutralizing and Fc-mediated immune effector function against EBOV _in vitro_ and protection against ... INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020. ... attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada...
Approved
Investigational
Matched Description: … , physical, and cognitive effects. ... pain, diarrhea, bloody stools, and vomiting. ... It was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.
Approved
Displaying drugs 2401 - 2425 of 15107 in total